Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03044977 · ClinicalTrials.gov registry record · Early Phase 1
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
A Early Phase 1 study of Neuroendocrine Tumor, Malignant and Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting, sponsored by David Bushnell.
- Active
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03044977 is a Early Phase 1 study of Neuroendocrine Tumor, Malignant and Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting that is active but no longer recruiting, run by David Bushnell. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03044977, a Early Phase 1 study of Neuroendocrine Tumor, Malignant and Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting, is active but no longer recruiting, sponsored by David Bushnell.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to identify the best tolerated doses of \[131\]Iodine-MIBG and \[90\]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated doses of these drugs (when combined together) is unknown.
Conditions Studied
Interventions
- DRUG 90Y-DOTA-3-Tyr-Octreotide
- DRUG 131I-MIBG
Study Locations (1)
Iowa
- Holden Comprehensive Cancer Center - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-05-07 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03044977
The ClinicalTrials.gov registry entry for NCT03044977 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David Bushnell, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neuroendocrine Tumor, Malignant appearing as the primary indexed condition, and to 2 interventions - of which 90Y-DOTA-3-Tyr-Octreotide is the first listed.
NCT03044977 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT03044977 about?
NCT03044977 is a clinical study titled "Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors". This study is designed to identify the best tolerated doses of \[131\]Iodine-MIBG and \[90\]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated ...
What is the current status of trial NCT03044977?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2017-05-07. Estimated completion is 2027-12.
What conditions does trial NCT03044977 study?
This clinical trial studies the following conditions: Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting.
What interventions are being tested in trial NCT03044977?
The interventions under investigation include: 90Y-DOTA-3-Tyr-Octreotide (DRUG), 131I-MIBG (DRUG).
Who is sponsoring clinical trial NCT03044977?
This trial is sponsored by David Bushnell, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03044977 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Neuroendocrine Tumor, Malignant
All registered trials for this condition
Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
All registered trials for this condition
Iowa
All trials with a study site in Iowa
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.